Filing Flows › CG Oncology (CGON) › Q3 2026 › vs Q3 2025
CG Oncology (CGON) Q3 2026 vs Q3 2025 (year over year)
CG Oncology's revenue fell $62K (-4%) from $1.7M in Q3 2025 to $1.6M in Q3 2026.
CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6M | $1.7M | −$62K | -4% |
| Other income, net | $6.4M | $7.3M | −$963K | -13% |
| Net loss | $56.9M | $43.8M | $13.1M | +30% |
| Costs & expenses | $64.9M | $52.8M | $12.1M | +23% |
| Operating costs | $64.9M | $52.8M | $12.1M | +23% |
| Cost of revenue | $2.7M | $1.6M | $1.1M | +69% |
| Research & development | $39.2M | $27.9M | $11.3M | +41% |
| General & admin | $23.0M | $23.3M | −$371K | -2% |
| Operating cash sources | $57.3M | $46.6M | $10.7M | +23% |
| Depreciation & amortization | $1.2M | $416K | $739K | +178% |
| Share-based compensation | $8.5M | $7.3M | $1.1M | +15% |
| Cash used in operations | $47.7M | $38.9M | $8.8M | +23% |
| Net loss absorbed | $56.9M | $43.8M | $13.1M | +30% |
| Working capital & other | $427K | $2.8M | −$2.4M | -85% |
Questions
How much did CG Oncology's revenue grow year over year in Q3 2026?
CG Oncology's revenue fell $62K (-4%) from $1.7M in Q3 2025 to $1.6M in Q3 2026.